M. Lavielle, Mixed Effects Models for the Population Approach: Models, Tasks, Methods and Tools. Chapman and Hall/CRC, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01122873

D. Mould and R. Upton, Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development. CPT Pharmacomet Syst Pharmacol, p.6, 2012.

P. Van-der-graaf, CPT: Pharmacometrics and Systems Pharmacology, CPT: Pharmacometrics & Systems Pharmacology, vol.1, issue.9, p.8, 2012.
DOI : 10.1038/psp.2012.8

M. Al-banna, A. Kelman, and B. Whiting, Experimental design and efficient parameter estimation in population pharmacokinetics, Journal of Pharmacokinetics and Biopharmaceutics, vol.46, issue.4, pp.347-60, 1990.
DOI : 10.1007/BF01062273

N. Holford, S. Ma, and B. Ploeger, Clinical Trial Simulation: A Review, Clinical Pharmacology & Therapeutics, vol.13, issue.2, pp.166-82, 2010.
DOI : 10.1111/j.1742-7843.2005.pto960314.x

F. Mentré, A. Mallet, and D. Baccar, Optimal design in random-effects regression models, Biometrika, vol.84, issue.2, pp.429-471, 1997.
DOI : 10.1093/biomet/84.2.429

F. Mentré, M. Chenel, E. Comets, J. Grevel, A. Hooker et al., Current Use and Developments Needed for Optimal Design in Pharmacometrics: A Study Performed Among DDMoRe???s European Federation of Pharmaceutical Industries and Associations Members, CPT: Pharmacometrics & Systems Pharmacology, vol.2, issue.6, p.46, 2013.
DOI : 10.1007/s11095-011-0659-3

J. Nyberg, C. Bazzoli, K. Ogungbenro, A. Aliev, S. Leonov et al., Methods and software tools for design evaluation in population pharmacokinetics-pharmacodynamics studies, British Journal of Clinical Pharmacology, vol.282, issue.1, 2014.
DOI : 10.1111/bcp.12352
URL : https://hal.archives-ouvertes.fr/inserm-00978789

C. Bazzoli, S. Retout, and F. Mentré, Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0. Comput Methods Programs Biomed, pp.55-65, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00431457

F. Mentré, T. Thuy, N. Lestini, G. Dumont, and C. Pfim, PFIM 4.0: new features for optimal design in nonlinear mixed effects models using R

J. Nyberg, S. Ueckert, E. Strömberg, S. Hennig, M. Karlsson et al., PopED: an extended, parallelized, nonlinear mixed effects models optimal design tool. Comput Methods Programs Biomed, pp.789-805, 2012.

I. Gueorguieva, K. Ogungbenro, G. Graham, S. Glatt, and L. Aarons, A program for individual and population optimal design for univariate and multivariate response pharmacokinetic-pharmacodynamic models. Comput Methods Programs Biomed, pp.51-61, 2007.

L. Foo and S. Duffull, Methods of Robust Design of Nonlinear Models with an Application to Pharmacokinetics, Journal of Biopharmaceutical Statistics, vol.253, issue.4, pp.886-902, 2010.
DOI : 10.1080/10543400600851880

L. Foo, J. Mcgree, J. Eccleston, and S. Duffull, Comparison of Robust Criteria for D-Optimal Designs, Journal of Biopharmaceutical Statistics, vol.253, issue.1, pp.1193-205, 2012.
DOI : 10.1023/A:1025701327672

L. Pronzato and E. Walter, Robust experiment design via maximin optimization, Mathematical Biosciences, vol.89, issue.2, 1988.
DOI : 10.1016/0025-5564(88)90097-1

M. Dodds, A. Hooker, and P. Vicini, Robust Population Pharmacokinetic Experiment Design, Journal of Pharmacokinetics and Pharmacodynamics, vol.99, issue.1, pp.33-64, 2005.
DOI : 10.1007/s10928-005-2102-z

M. Chang, Adaptive Design Theory and Implementation Using SAS and R. 1 edition. Boca Raton: Chapman and Hall/CRC, 2007.

L. Foo and S. Duffull, Adaptive Optimal Design for Bridging Studies with an Application to Population Pharmacokinetic Studies, Pharmaceutical Research, vol.34, issue.6, pp.1530-1573, 2012.
DOI : 10.1007/s11095-011-0659-3

S. Zamuner, D. Iorio, V. Nyberg, J. Gunn, R. Cunningham et al., Adaptive-Optimal Design in PET Occupancy Studies, Clinical Pharmacology & Therapeutics, vol.87, issue.5, pp.563-71, 2010.
DOI : 10.1111/j.2005.0906-7590.04112.x

V. Fedorov, Y. Wu, and R. Zhang, Optimal dose-finding designs with correlated continuous and discrete responses, Statistics in Medicine, vol.72, issue.3, pp.217-251, 2012.
DOI : 10.1002/sim.4388

T. Chen, Optimal three-stage designs for phase II cancer clinical trials, Statistics in Medicine, vol.16, issue.23, pp.2701-2712, 1997.
DOI : 10.1002/(SICI)1097-0258(19971215)16:23<2701::AID-SIM704>3.0.CO;2-1

C. Dumont, M. Chenel, and F. Mentré, Two-stage Adaptive Designs in Nonlinear Mixed Effects Models: Application to Pharmacokinetics in??Children, Communications in Statistics - Simulation and Computation, vol.2, issue.5
DOI : 10.1038/clpt.2010.9
URL : https://hal.archives-ouvertes.fr/inserm-01076940

L. Bueno, D. De-alwis, C. Pitou, J. Yingling, M. Lahn et al., Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-?? kinase antagonist, in mice, European Journal of Cancer, vol.44, issue.1, pp.142-50, 1990.
DOI : 10.1016/j.ejca.2007.10.008

I. Gueorguieva, A. Cleverly, A. Stauber, S. Pillay, N. Rodon et al., Defining a therapeutic window for the novel TGF-?? inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model, British Journal of Clinical Pharmacology, vol.3, issue.Suppl., pp.796-807, 2014.
DOI : 10.1111/bcp.12256

T. Mielke, R. Schwabe, A. Giovagnoli, A. Atkinson, and B. Torsney, Some Considerations on the Fisher Information in Nonlinear Mixed Effects Models editors. mODa 9 ? Advances in Model- Oriented Design and Analysis [Internet]. Physica-Verlag HD Available from, pp.129-165, 2010.

J. Hoeting, D. Madigan, A. Raftery, and C. Volinsky, Bayesian model averaging: a tutorial, Stat Sci, vol.14, issue.4, pp.382-417, 1999.

M. Tod and J. Rocchisani, Comparison of ED, EID, and API criteria for the robust optimization of sampling times in pharmacokinetics, Journal of Pharmacokinetics and Biopharmaceutics, vol.25, issue.4, pp.515-552, 1997.
DOI : 10.1023/A:1025701327672